DUBLIN, Calif.--(BUSINESS WIRE)-- SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S.J. Manuso, Ph.D., president and chief executive officer, will present at BioEquity Europe 2011 on Monday and Tuesday, May 23rd and 24th in Paris.
SuperGen's corporate presentation will take place on May 23 at 11:00 a.m. CEST. In addition, Dr. Manuso will participate in a panel discussion titled, “Strategy: Squaring the Circle” about building companies to study disease biology based on platform technology, on May 24 at 1:45 p.m. CEST. More information on the panel can be found at http://www.biocentury.com/Conferences.
About SuperGen
SuperGen is a pharmaceutical company dedicated to discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. On April 6, 2011, SuperGen entered into a definitive merger agreement to acquire Astex Therapeutics Limited, a UK based biotechnology company. The transaction is subject to customary regulatory, legal and shareholder approvals. For more information about SuperGen, please visit http://www.supergen.com.
CONTACT:
SuperGen, Inc.
Timothy L. Enns, 925-560-2810
Senior Vice President
Corporate Communications & Business Dev.
[email protected]
Susanna Chau, 925-560-2845
Manager
Investor Relations
[email protected]
or
The Trout Group
Alan Roemer, 646-378-2945
Senior Vice President
[email protected]
or
Fleishman-Hillard
Michael Ares, 404-739-0133
Senior Vice President
[email protected]
KEYWORDS: United States Europe North America California France
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical
MEDIA:
| Logo |